AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01211197
Drug: C: BI 10773 / metformin tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BI 10773 / metformin fixed dose combination tablet after a high fat, high caloric meal
Trial: NCT01211197
Drug: B: BI 10773 tablet and metformin tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BI 10773 and metformin single tablets, administered together in fasted state
Trial: NCT01211197
Drug: A: BI 10773 / metformin tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BI 10773 / metformin fixed dose combination tablet in fasted state
Trial: NCT02977208
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients undergoing chronic treatment with gabapentin are being recruited.
Trial: NCT01839500
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab administered in accordance with routine care practice.
Trial: NCT02301650
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: mothers use Lamivudine in late pregnancy
Trial: NCT02301650
Drug: Telbivudine
RxNorm normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: mothers use Telbivudine in late pregnancy
Trial: NCT02301650
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: mothers use Tenofovir in late pregnancy
Trial: NCT01756612
Drug: Methoxy Polyethylene Glycol-Epoetin Beta
RxNorm normalized name: Methoxy polyethylene glycol-epoetin beta
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methoxy polyethylene glycol-epoetin beta will be administered at the discretion of treating physician. Study protocol does not specify any treatment regimen.
Trial: NCT03170960
Drug: cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Supplied as 60-mg and 20-mg tablets; administered orally daily at dose levels of 20 mg, 40 mg, or 60 mg.
Trial: NCT00516451
Drug: BMS-690514
RxNorm normalized name: BMS-690514
DrugBank: BMS-690514 (DB11665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 100, 200, 250 or 300 mg once daily, 29 days or more
Trial: NCT02683941
Drug: Lanreotide (Autogel formulation)
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 120mg every 28 days until disease progression, death, or unacceptable toxicity
Trial: NCT05189002
Drug: Dimolegin 40 mg
RxNorm normalized name: Adagloxad simolenin
DrugBank: Adagloxad simolenin (DB16082)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimolegin - DD217 - 40 mg
Trial: NCT05189002
Drug: Dimolegin 60 mg
RxNorm normalized name: Adagloxad simolenin
DrugBank: Adagloxad simolenin (DB16082)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimolegin - DD217 - 60 mg
Trial: NCT05189002
Drug: Fragmin
RxNorm normalized name: Fragmin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fragmin 5000 IU in 0.2 ML Prefilled Syringe
Trial: NCT01201863
Drug: Androgel (Testosterone Gel)
RxNorm normalized name: testosterone Topical Gel [Androgel]
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 gram stickpacks administered with starting dosage of 5g increasing to a max of 10g.
Trial: NCT01868568
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered subcutaneously (s.c., under the skin).
Trial: NCT01868568
Drug: insulin degludec/insulin aspart 30
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single dose administered subcutaneously (s.c., under the skin).
Trial: NCT01868568
Drug: insulin degludec/insulin aspart 40
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single dose administered subcutaneously (s.c., under the skin).
Trial: NCT03170960
Drug: atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
Trial: NCT02550665
Drug: donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: using different titration method for the first 4 weeks, and after the 4 weeks, 23mg/day orally
Trial: NCT01868568
Drug: insulin degludec/insulin aspart 45
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single dose administered subcutaneously (s.c., under the skin).
Trial: NCT01868568
Drug: insulin degludec/insulin aspart 55
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single dose administered subcutaneously (s.c., under the skin).
Trial: NCT01868568
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single dose administered subcutaneously (s.c., under the skin).
Trial: NCT01868568
Drug: biphasic insulin aspart 30
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single dose administered subcutaneously (s.c., under the skin).
Trial: NCT00587665
Drug: ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single IV dose of 0.1 mg/kg of ketamine
Trial: NCT04221971
Drug: chemotherapy combined with NK cells infusion
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy combined with NK cells infusion
Trial: NCT03170960
Drug: cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage
Trial: NCT00866723
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00102609
Drug: Trabectedin
RxNorm normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trabectedin 0.9 to 1.3 mg/m2 administered intravenously on Day 1 every 3 weeks for up to 6 cycles
Trial: NCT00102609
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 20 mg administered intravenously within 1 hour before the start of doxorubicin
Trial: NCT03170960
Drug: cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Supplied as 60-mg and 20-mg tablets; administered orally daily at 60 mg qd
Trial: NCT03908242
Drug: salvianolic acid A
RxNorm normalized name: Salvianolic acid A
DrugBank: Salvianolic acid A (DB15246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
Trial: NCT01657682
Drug: Crenolanib besylate
RxNorm normalized name: mesylate
DrugBank: Crenolanib (DB11832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crenolanib besylate, 100 mg TID, taken orally at least 30 minutes pre- or post- meal. Patients will complete a daily diary to record the date, time and amount (number of tablets) of crenolanib taken and eating schedule.~Concurrent hydroxyurea (maximum 5g total daily dose x 14 days) is permitted during the first 28 days of study therapy.
Trial: NCT04876534
Drug: Tocilizumab 20 Mg/mL Intravenous Solution
RxNorm normalized name: tocilizumab 20 mg/mL intravenous solution
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous administration
Trial: NCT00714233
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 425mg. capsules, 2 capsules BID x 24 weeks
Trial: NCT00714233
Drug: Oral Contraceptive Pills (Yasmin)
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yasmin oral contraceptive tabs; 1 tab daily x 24 weeks
Trial: NCT01272804
Drug: PF-04937319
RxNorm normalized name: PF-04937319
DrugBank: PF-04937319 (DB15009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be dosed with PF-04937319 for 14 days. The doses planned are 10, 30, 100 and 300 mg QD. All doses will be administered as tablets (10 and 100 mg strengths). In each Cohort, 9 patients will receive PF 04937319 and 3 will receive placebo. An additional cohort of 12 patients (9 active, 3 placebo) may be performed to explore a QD or BID dose. The dose for this additional cohort could be a dose already studied or a new dose that is within the exposure stopping criteria.
Trial: NCT02730962
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin 3 times a day for 7 days
Trial: NCT02730962
Drug: Neomycin
RxNorm normalized name: Neomycin
DrugBank: Neomycin (DB00994)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neomycin 3 times a day for 1 day
Trial: NCT00856180
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01894958
Drug: NNZ-2566
RxNorm normalized name: NNZ-2591
DrugBank: NNZ-2591 (DB15601)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials or 3g in 30mL bottles) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
Trial: NCT00266318
Drug: Interferon Alfacon-1 and Ribavirin
RxNorm normalized name: interferon alfacon-1
DrugBank: Interferon alfacon-1 (DB00069)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00984867
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg tablet, oral, once daily, 48 weeks
Trial: NCT01668797
Drug: Brexpiprazole
RxNorm normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brexpiprazole tablets 1 to 4 mg /day
Trial: NCT00406653
Drug: abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dextrose 5% in water, intravenous (IV).~Placebo on days Induction Period (IP)-1, IP-15,IP-29, IP-57;~3 mg/kg on days IP-1, IP-15,IP-29, IP-57;~\~10 mg/kg on days IP-1, IP-15,IP-29, IP-57,~or 30 mg/kg on days IP-1,IP-15 and \~10 mg/kg on days IP-29, IP-57.~Induction Period 3 months~Maintenance Period 12 months
Trial: NCT00406653
Drug: abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: \~10 mg/kg, every 28 days.~Open- Label Extension Period until the drug is marketed for Crohn's Disease (CD)or the CD development program for abatacept is discontinued
Trial: NCT01603186
Drug: Quetiapine Fumarate Tablets 25 mg
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg tablet once a day
Trial: NCT01603186
Drug: Quetiapine Fumarate
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg tablet once a day
Trial: NCT01004614
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3rd OD 5 mg tablet single oral dose administered with water
Trial: NCT01004614
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2nd OD 5 mg tablet single oral dose administered with water
Trial: NCT01004614
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3rd OD 5 mg tablet single oral dose administered without water
Trial: NCT01004614
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2nd OD 5 mg tablet single oral dose administered without water
Trial: NCT01257165
Drug: Zopiclone
RxNorm normalized name: zopiclone
DrugBank: Zopiclone (DB01198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zopiclone pill 5 or 10 mg, given orally as a single dose.
Trial: NCT03582137
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects randomized to this arm will receive Cannabidiol Cannabis extract oral solution
Trial: NCT00938561
Drug: Inulin
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04865562
Drug: testosterone propionate
RxNorm normalized name: Testosterone Propionate
DrugBank: Testosterone propionate (DB01420)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg/0.1mL solution, to be administered intranasally
Trial: NCT00483262
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by injection once a week for 4 weeks (a cycle equals 5 weeks) for up to 8 cycles
Trial: NCT00558753
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.
Trial: NCT00377598
Drug: TAK-583
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks
Trial: NCT00377598
Drug: TAK-583
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-583 25 mg, tablets, orally, once daily for up to 8 weeks
Trial: NCT00377598
Drug: TAK-583
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-583 50 mg, tablets, orally, once daily for up to 8 weeks
Trial: NCT00377598
Drug: TAK-583
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-583 100 mg, tablets, orally, once daily for up to 8 weeks
Trial: NCT02923869
Drug: Levobupivacaine
RxNorm normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children will receive 0.15 ml/kg of 0.2% Levobupivacaine through bilateral suprazygomatic MNB.
Trial: NCT02923869
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children will receive 0.15 ml/kg of 0.2% Bupivacaine through bilateral suprazygomatic MNB.
Trial: NCT00257816
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (First stage of accrual, 6 patients)-2 mg/m2 IV on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)~If none or 1 of the 6 patients in the first Stage of accrual finish the prescribed therapy in over 8 weeks, then the second Stage of accrual (an additional 6 patients) will increase the Topotecan dose to 3 mg/m2 on days 1, 8, 15, 22, 29 and once during parametrical boost (6 cycles). If 2 or 3 of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, the dose of the Topotecan will remain the same in the second Phase of accrual. If 4 or more of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, there will be no second phase of accrual.
Trial: NCT00257816
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/m2 IV (Maximum total dose of 70 mg) on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)
Trial: NCT01210079
Drug: Gabapentin;
RxNorm normalized name: Gabapentin;Gabapentin 300 MG; 600 MG Oral Tablet
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin titrated to daily dose of 2400mg PO over 1 week with established dose taken daily for 5 weeks.
Trial: NCT03587194
Drug: Otezla
RxNorm normalized name: Otezla
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Otezla 30mg BID
Trial: NCT00918190
Drug: Ondansetron, Dexamethasone
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of ondansetron and dexamethasone as combined antiemetics
Trial: NCT00918190
Drug: Midazolam, dexamethasone
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: use of midazolam and dexamethasone as combined antiemetic
Trial: NCT00530777
Drug: valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
Trial: NCT03722576
Drug: Vidofludimus calcium
RxNorm normalized name: Vidofludimus
DrugBank: Vidofludimus (DB15446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the 6-month treatment period, subjects will receive 30 mg VC orally once daily. This will be preceded by a lead-in dosing period where subjects will receive 15 mg VC once daily for 1 week.
Trial: NCT00602160
Drug: FAHF-2 (TM)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: We propose to test 10 tablets administered orally three times daily (t.i.d.) for 6 months in the Phase II study. The subjects will be randomized to 1 of 2 groups; FAHF-2 or Placebo group.~Both groups will undergo physician supervised Double-blinded placebo controlled food challenges, once during screening before starting treatment and again after 6 months of therapy.
Trial: NCT00151619
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03382821
Drug: Dexamethasone Sodium Phosphate 10 MG/ML
RxNorm normalized name: dexamethasone sodium phosphate 10 mg/mL INJECTION KIT
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transforaminal ESI with dexamethasone 1.5 mL of dexamethasone sodium phosphate in group #1
Trial: NCT03382821
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mL of 1% lidocaine as diluent for the steroid in both group #1 and group #2
Trial: NCT03382821
Drug: Triamcinolone Acetonide 40mg/mL
RxNorm normalized name: TRIAMCINOLONE ACETONIDE 40MG/ML INJ,SUSP
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transforaminal catheter-targeted ESI with triamcinolone acetonide 2 mL in group #2
Trial: NCT03354533
Drug: L-fucose
RxNorm normalized name: L-FUCOSE
DrugBank: Fucose (DB15236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ORL-1F
Trial: NCT00037700
Drug: anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01675778
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a fixed dose (1 mg) of hydromorphone will be given to the study subjects
Trial: NCT00037700
Drug: pegsunercept
RxNorm normalized name: Pegsunercept
DrugBank: Pegsunercept (DB06611)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00658099
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
Trial: NCT00599677
Drug: Itopride
RxNorm normalized name: itopride
DrugBank: Itopride (DB04924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each pill weighs 50mg, once a pill, three times a day. The pills are taken half an hour before meals, and be taken 4 weeks continuously.
Trial: NCT02668185
Drug: NK3R antagonist - AZD4901
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neurokinin 3 receptor antagonist
Trial: NCT00066989
Drug: Staphylococcus aureus Immune Globulin (Human) 5%
DrugBank: Staphylococcus aureus immune globulin (human) (DB17755)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02092324
Drug: Ruxolitinib Phosphate
RxNorm normalized name: Ruxolitinib Phosphate
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00333385
Drug: ceftazidime
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00167960
Drug: Piperacillin/tazobactam and other β-lactam/β-lactamase
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01145755
Drug: AZD2066
RxNorm normalized name: AZD2066
DrugBank: AZD2066 (DB17078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg once daily
Trial: NCT00626639
Drug: palifermin
RxNorm normalized name: palifermin
DrugBank: Palifermin (DB00039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered by intravenous (IV) bolus injection
Trial: NCT00626639
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/m\^2 intravenously (IV) on days 1, 22 and 43.
Trial: NCT01145755
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg once daily
Trial: NCT00827567
Drug: RAD 001
RxNorm normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD 001-10 mg by mouth once everyday